TMBRQ — Trex Wind-Down Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$2.52m
- $0.08m
Brief: Timber Pharmaceuticals Says Cash Position Of $10.4 Million At Dec 31, 2020
Timber Pharma: Up as partner signs supply agreement for rare skin disease drug
Brief: Timber Pharmaceuticals' Development Partner, Aft Pharmaceuticals, Enter Licensing Agreement For Pascomer In Europe
Brief: Timber Pharmaceuticals Announces 50% Enrollment In Phase 2B Control Study In Congenital Ichthyosis
U.S. STOCKS ON THE MOVE-Acorda Therapeutics, Exxon Mobil, Timber Pharma, Marker Therapeutics
U.S. STOCKS ON THE MOVE-Apple, Marathon Patent Group, Alibaba, Party City
Timber Pharma: Jumps on orphan drug tag for systemic sclerosis treatment
Brief: Timber Pharma Gets Orphan Drug Designation From FDA For Tmb-003 For Treatment Of Systemic Sclerosis
Brief: Timber Pharmaceuticals Receives Orphan Drug Designation From U.S. FDA For Tmb-003 For The Treatment Of Systemic Sclerosis
Brief: Timber Pharmaceuticals Inc - Receives Notice Of Allowance From U.S. Patent And Trademark Office For Lead Asset
Brief: Timber Pharmaceuticals Inc Files For Shelf Of Up To 11.4 Million Shares By Selling Stockholders
Brief: Timber Pharmaceuticals Reports Third Quarter 2020 Financial Results
AMEX HALT EQUIPMENT CHANGEOVER LAST 1.01500
Brief: Timber Pharmaceuticals Receives Notice Of Allowance From U.S. Patent And Trademark Office For BPX-01 And BPX-04
Brief: Timber Pharmaceuticals Expect To Complete Enrollment Of Patients In Both TMB-001 And TMB-002 Studies During Early Months Of 2021
Brief: Timber Pharmaceuticals Files For Non-Timely 10-Q
Brief: Timber Pharma Says European Patent Office Intends To Grant Patent For Bpx-01, Bpx-04
Brief: Timber Pharmaceuticals Announces All Control Study Sites Open And Enrolling Patients With Moderate To Severe Congenital Ichthyosis
BioPharmX: Gains on patent win